Latest Period
Q2 2026
Security Snapshot
Bolt Biotherapeutics, Inc. - Common Stock, $0.00001 par value (BOLT) Institutional Ownership
CUSIP: 097702203
13F Institutional Holders and Ownership History from Q2 2025 to Q2 2026
Institutions Reporting
23
Shares (Excl. Options)
596,527
Price
$3.85
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.00001 par value
- Symbol
- BOLT on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 596,527
- Total 13F value
- $2,309,955
- Portfolio coverage rank
- 0%
- Share change
- -16,725
- Value change
- -$74,708
- Number of holders
- 23
- Shares outstanding
- 1,922,515
- SEC-reported price per share
- $3.85
- Insider filing price
- $3.85
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- BOLT - Bolt Biotherapeutics, Inc. - Common Stock, $0.00001 par value is tracked under CUSIP 097702203.
- 23 institutions reported positions in Q2 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 24 to 23 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $2,488,203 to $2,309,955.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 23 institutions filings for Q2 2026.
Security key
097702203
Latest holder period
Q2 2026
13F holders
23
13D/G owners
3
CIK / CUSIP context first
Open Q2 2026 holders
BOLT full holder history
Bolt Biotherapeutics, Inc. SEC filings
Bolt Biotherapeutics, Inc. company facts
Bolt Biotherapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 097702203:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
BOLT
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 5.1% | $379,894 | 98,625 | Renaissance Technologies LLC | 24 Jun 2026 | |||
| Pivotal bioVenture Partners Fund I, L.P. | 4.6% | -30% | $478,373 | -$222,181 | 87,486 | -32% | Nan Fung Group Holdings Limited | 24 Feb 2026 |
| TANG CAPITAL MANAGEMENT LLC | 3.5% | -58% | $355,790 | -$531,990 | 66,879 | -60% | TANG CAPITAL MANAGEMENT, LLC | 30 Sep 2025 |
As of 30 Jun 2026, 23 institutional investors reported holding 596,527 shares of Bolt Biotherapeutics, Inc. - Common Stock, $0.00001 par value (BOLT). This represents 31% of the company’s total 1,922,515 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
31%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Sofinnova Investments, Inc. | 7.2% | 137,721 | 0% | 0.03% | $530,226 |
| RENAISSANCE TECHNOLOGIES LLC | 5.1% | 98,625 | +28% | 0% | $379,706 |
| Vivo Capital, LLC | 3.8% | 72,414 | 0% | 0.03% | $278,794 |
| CITADEL ADVISORS LLC | 3% | 56,903 | +463% | 0% | $219,077 |
| T3 Companies, LLC | 2% | 38,000 | 0% | 0.17% | $146,300 |
| Board of Trustees of The Leland Stanford Junior University | 1.9% | 35,977 | 0% | 0.03% | $138,511 |
| Pfizer Inc | 1.6% | 31,305 | 0% | 0.08% | $133,832 |
| Lynx1 Capital Management LP | 1.6% | 30,800 | 0% | 0.01% | $118,580 |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | 1.4% | 27,500 | 0% | 0.08% | $105,875 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.99% | 19,119 | -34% | 0% | $73,622 |
| Shay Capital LLC | 0.8% | 15,438 | +3.6% | 0.01% | $59,436 |
| BlackRock, Inc. | 0.51% | 9,711 | 0% | 0% | $37,388 |
| VANGUARD CAPITAL MANAGEMENT LLC | 0.37% | 7,060 | 0% | 0% | $27,181 |
| Nan Fung Group Holdings Ltd | 0.26% | 5,000 | -83% | 0.01% | $19,250 |
| MORGAN STANLEY | 0.16% | 3,145 | -1.4% | 0% | $12,108 |
| VANGUARD FIDUCIARY TRUST CO | 0.16% | 3,095 | 0% | 0% | $11,916 |
| NewEdge Advisors, LLC | 0.13% | 2,530 | 0% | $9,740 | |
| Tower Research Capital LLC (TRC) | 0.09% | 1,710 | +56% | 0% | $6,584 |
| UBS Group AG | 0.01% | 255 | -68% | 0% | $982 |
| SBI Securities Co., Ltd. | 0.01% | 130 | +1200% | 0% | $501 |
| JPMORGAN CHASE & CO | 0% | 42 | 0% | 0% | $165 |
| CITIGROUP INC | 0% | 41 | 0% | $158 | |
| BARCLAYS PLC | 0% | 6 | 0% | 0% | $23 |
| Vanguard Global Advisers, LLC | 0% | 0 | -100% | $0 | |
| Pivotal bioVenture Partners Investment Advisor LLC | 0% | 0 | -100% | $0 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
5
Latest
Q2 2026
Rows shown
1-5 of 5
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 596,527 | $2,309,955 | -$74,708 | $3.85 | 23 |
| 2026 Q1 | 613,252 | $2,488,203 | +$42,876 | $4.04 | 24 |
| 2025 Q4 | 602,538 | $3,295,047 | -$1,398,347 | $5.47 | 21 |
| 2025 Q3 | 804,036 | $4,277,487 | -$449,347 | $5.32 | 24 |
| 2025 Q2 | 887,525 | $5,096,477 | +$5,096,477 | $5.77 | 24 |